A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome
NCT00220363
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Overactive Bladder Syndrome
- less than 8 micturitions in 24 hours
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Birmingham, Alabama
- Gilbert, Arizona
- Gilbert, Arizona
- Litchfield Park, Arizona
- Mesa, Arizona
- Phoenix, Arizona
- Tucson, Arizona
- La Mesa, California
- Newport Beach, California
- San Bernardino, California
- San Diego, California
- San Diego, California
- Aurora, Colorado
- Denver, Colorado
- Jupiter, Florida
- Orange City, Florida
- West Palm Beach, Florida
- Dunwoody, Georgia
- Evansville, Indiana
- Jeffersonville, Indiana
- Newburgh, Indiana
- Des Moines, Iowa
- Iowa City, Iowa
- Baltimore, Maryland
- Owings Mills, Maryland
- Watertown, Massachusetts
- Flint, Michigan
- St. Clair Shores, Michigan
- Troy, Michigan
- Utica, Michigan
- West Bloomfield, Michigan
- West Bloomfield, Michigan
- Minneapolis, Minnesota
- Omaha, Nebraska
- Sewell, New Jersey
- Albany, New York
- Garden City, New York
- Kingston, New York
- New York, New York
- Poughkeepsie, New York
- Syracuse, New York
- Williamsville, New York
- Durham, North Carolina
- Greensboro, North Carolina
- Fargo, North Dakota
- Fargo, North Dakota
- Cincinnati, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Bethany, Oklahoma
- Portland, Oregon
- Bala Cynwyd, Pennsylvania
- Camp Hill, Pennsylvania
- Pittsburgh, Pennsylvania
- Charleston, South Carolina
- Greer, South Carolina
- Austin, Texas
- Austin, Texas
- Houston, Texas
- Tacoma, Washington
- Madison, Wisconsin
- Milwaukee, Wisconsin
- Antwerpen,
- Edegem,
- Leuven,
- Salvador, BA
- Curitiba, PR
- Rio de Janeiro, RJ
- Porto Alegre, RS
- São Paulo, SP
- Campos do Jordão, São Paulo
- Victoria, British Columbia
- Winnipeg, Manitoba
- Barrie, Ontario
- North Bay, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Chicoutimi, Quebec
- Pointe-Claire, Quebec
- Sherbrooke, Quebec
- Medellin, Antioquia
- Bogota, Cundinamarca
- Berlin,
- Frankfurt,
- Goettingen,
- Hagenow,
- Lauenburg,
- Leipzig,
- Oberursel,
- Wiesbaden,
- Ioannina, Ipiros
- Patras,
- Thessaloniki,
- Ludhiana, Punjab
- Lucknow, Uttar Pradesh
- Lucknow, Uttar Pradesh
- New Delhi,
- Bucheon-si, Gyunggi-do
- Pusan,
- Seoul,
- Seoul,
- Kuching, Sarawak
- Kuching, Sarawak
- Roermond,
- Tilburg,
- Zutphen,
- Bodø,
- Oslo,
- Cebu City, Cebu
- Bacolod City,
- Makati City,
- Manila,
- Manila,
- Quezon City,
- Bialystok,
- Gdansk,
- Gdansk,
- Lodz,
- Myslowice,
- Wroclaw,
- Singapore,
- Singapore,
- Banska Bystrica,
- Bratislava,
- Martin,
- Piestany,
- Skalica,
- Martorell, Barcelona
- Getafe, Madrid
- Manacor, Palma de Mallorca
- Boras,
- Jonkoping,
- Skovde,
- Stockholm,
- Stockholm,
- Ratchathewi, Bangkok
- Amphoe Mueang, Chiang Mai
- Monheim,
- Monheim,
- RTP, North Carolina
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome | |||
Official Title ICMJE | A Phase 3, Parallel Group, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome | |||
Brief Summary | The trial consisted of a 2 week Run-In period, 12 week double-blind Treatment period and 2 week Safety Follow-Up period. Subjects were randomized to one of 4 treatment arms receiving either fesoterodine (SPM 907) 4mg, fesoterodine 8mg, active control (tolterodine SR 4mg) or placebo during the Double-Blind Treatment Period. Two primary efficacy variables will be assessed for submission in the United States: change in the average number of micturitions (frequency) per 24 hours and the change in the average number of urge incontinence episodes per 24 hours. For the submissions in the European Union, the first primary variable will be the change in the average number of micturitions (frequency) per 24 hours and the co-primary variable is the treatment response, based on a treatment benefit scale. All continuous variables will be measured as changes from baseline to value after 12 weeks of treatment. The most important safety variables included the assessment of adverse events, laboratory parameters, changes in ECG, physical exams and measurement of residual urine. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double | |||
Condition ICMJE | Overactive Bladder Syndrome | |||
Intervention ICMJE | Drug: SPM 907 | |||
Study Arms ICMJE | Not Provided | |||
Publications * |
| |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | Not Provided | |||
Original Enrollment ICMJE | Not Provided | |||
Actual Study Completion Date ICMJE | February 2005 | |||
Actual Primary Completion Date | February 2005 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | Not Provided | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Germany | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00220363 | |||
Other Study ID Numbers ICMJE | SP583 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | April 2008 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |